|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/14/2012 9:50:22 AM
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (the “Company”), a world leader in oral care probiotics, today announced that the Company has entered into a new three year contract agreement with Pharmacos Exakta, S.A. de C.V. Under the terms of the agreement, Pharmacos Exakta will be the exclusive distributor of Oragenics’ oral care probiotics for pets in Mexico under a private label. The pet product will contain ProBiora3®; Oragenics’ patented proprietary blend of three probiotics specifically designed for oral health. Pharmacos Exakta S.A. de C.V. manufactures and markets ophthalmic and other pharmaceutical products for government and private markets. The company was founded in 1957 and is based in Guadalajara, Mexico. As of February 17, 2010, Pharmacos Exakta S.A. de C.V. operates as a subsidiary of Opko Health, Inc.
|
|
|
|
|
|
|
|
|
|
|